Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
California announces state‑backed low‑cost insulin and advances rural health transformation plans
Summary
At a Health Care Affordability Board meeting, staff announced California’s Calyrex biosimilar insulin program — state‑backed glargine pens at a target retail price of $55 per five‑pack starting Jan. 1, 2026 — and described a federal rural health transformation application focused on hub‑and‑spoke care models, technology, and workforce development.
Director Landsberg told the Health Care Affordability Board that California will offer a state‑backed low‑cost insulin under the Calyrex initiative beginning Jan. 1, 2026, with insulin glargine pens priced at a maximum of $55 for a five‑pack and pharmacies able to purchase them for $45. "California has become the first state to offer its own low cost insulin starting on 01/01/2026," Landsberg said, framing the program as a way to reduce reliance on coupons and rebates and improve medication affordability for underinsured and uninsured residents.
The director credited state leaders and the Calyrex team for advancing a…
Already have an account? Log in
Subscribe to keep reading
Unlock the rest of this article — and every article on Citizen Portal.
- Unlimited articles
- AI-powered breakdowns of topics, speakers, decisions, and budgets
- Instant alerts when your location has a new meeting
- Follow topics and more locations
- 1,000 AI Insights / month, plus AI Chat
